OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+72%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$766M
AUM Growth
+$766M
(+50%)
Cap. Flow
+$40.1M
Cap. Flow
% of AUM
5.24%
Top 10 Holdings %
Top 10 Hldgs %
55.55%
Holding
68
New
13
Increased
17
Reduced
11
Closed
9
Top Buys
| 1 |
Ocular Therapeutix
OCUL
|
$10.9M |
| 2 |
Cytokinetics
CYTK
|
$7.77M |
| 3 |
FSDC
FS Development Corp. Class A Common Stock
FSDC
|
$7.75M |
| 4 |
Protagonist Therapeutics
PTGX
|
$7.02M |
| 5 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
$6.76M |
Top Sells
| 1 |
ATXI
Avenue Therapeutics, Inc. Common Stock
ATXI
|
$10.7M |
| 2 |
APTO
Aptose Biosciences, Inc.
APTO
|
$4.38M |
| 3 |
Fulcrum Therapeutics
FULC
|
$4.26M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
$3.76M |
| 5 |
MacroGenics
MGNX
|
$3.58M |
Sector Composition
| 1 | Healthcare | 95.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ocular Therapeutix
OCUL
$2.12B
| $135M | 17.6% | 6,510,000 +525,800 | +9% | +$10.9M |
|
2
Protara Therapeutics
TARA
$120M
| $61.9M | 8.09% | 2,558,472 | – | – |
|
|
EIDX
3
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $41.5M | 5.42% | 315,550 | – | – |
|
4
Eton Pharmaceutcials
ETON
$464M
| $32.8M | 4.29% | 4,040,000 +400,000 | +11% | +$3.25M |
|
5
Codexis
CDXS
$246M
| $30.6M | 3.99% | 1,400,000 | – | – |
|
6
Cardiff Oncology
CRDF
$140M
| $29.9M | 3.91% | 1,662,500 -69,100 | -4% | -$1.24M |
|
|
TCON
7
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $29.5M | 3.85% | 2,518,371 +504,933 | +25% | +$5.91M |
|
|
CCXI
8
DELISTED
ChemoCentryx, Inc.
CCXI
| $21.7M | 2.83% | 350,000 -6,000 | -2% | -$372K |
|
|
AFIB
9
DELISTED
Acutus Medical, Inc. Common Stock
AFIB
| $21.6M | 2.82% | 749,990 | – | – |
|
10
Harrow
HROW
$1.44B
| $21M | 2.75% | 3,065,416 +106,416 | +4% | +$730K |
|
11
TG Therapeutics
TGTX
$4.65B
| $20.2M | 2.63% | 387,500 -2,500 | -0.6% | -$130K |
|
12
Xoma
XOMA
$392M
| $20.1M | 2.62% | 455,000 | – | – |
|
13
Neurogene
NGNE
$264M
| $19.5M | 2.55% | 1,386,300 | – | – |
|
|
CMRX
14
DELISTED
Chimerix, Inc.
CMRX
| $19.1M | 2.5% | 3,956,500 +115,000 | +3% | +$555K |
|
15
Celldex Therapeutics
CLDX
$1.47B
| $17.4M | 2.27% | 992,000 | – | – |
|
16
Stereotaxis
STXS
$261M
| $15.4M | 2.01% | 3,021,436 | – | – |
|
|
DCPH
17
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $12.7M | 1.66% | 222,000 | – | – |
|
18
Fortress Biotech
FBIO
$76.8M
| $12.3M | 1.61% | 3,887,500 +57,500 | +2% | +$182K |
|
|
19
Cytokinetics
CYTK
$4.23B
| $12.1M | 1.58% | 582,800 +374,000 | +179% | +$7.77M |
|
|
MYOV
20
DELISTED
Myovant Sciences Ltd.
MYOV
| $10.5M | 1.37% | 682,500 | – | – |
|
|
LUMO
21
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $10M | 1.31% | 281,287 +40,395 | +17% | +$1.44M |
|
22
Seres Therapeutics
MCRB
$166M
| $9.8M | 1.28% | 335,312 | – | – |
|
|
BHVN
23
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $9.77M | 1.28% | 114,000 -350 | -0.3% | -$30K |
|
24
KalVista Pharmaceuticals
KALV
$678M
| $8.93M | 1.17% | 470,203 | – | – |
|
25
Vaxcyte
PCVX
$4B
| $8.91M | 1.16% | 335,200 +22,200 | +7% | +$590K |
|